Osteoporosis on antiresorptives (MRONJ risk)
Medication-related osteonecrosis of the jaw (MRONJ) is exposed bone (or bone probeable through a fistula) in the maxillofacial region persisting >8 weeks in a patient exposed to antiresorptive or antiangiogenic agents, without head/neck radiation. Risk is stratified by indication: osteoporosis dosing (oral bisphosphonates like alendronate — MRONJ is RARE) vs oncology dosing (high-dose IV bisphosphonates/denosumab — much HIGHER risk). AAOMS 2022 position paper is the major reference. Prevention strategy: risk assessment + atraumatic technique + oral health optimization.
The full condition entry includes
- Safe vs avoid lists: antibiotics, analgesics, local anesthetics
- Vasoconstrictor limits and treatment modifications
- Pre/intra/post-op monitoring and deferral criteria
- Emergency management, explained for study
More medical conditions in dentistry
Dentalverse is an educational resource for dental students and dentists. This page is a study reference — it is not medical advice and does not replace clinical judgment. Always follow your institution's protocols and your supervisor's guidance.